JP2020516276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516276A5 JP2020516276A5 JP2019555484A JP2019555484A JP2020516276A5 JP 2020516276 A5 JP2020516276 A5 JP 2020516276A5 JP 2019555484 A JP2019555484 A JP 2019555484A JP 2019555484 A JP2019555484 A JP 2019555484A JP 2020516276 A5 JP2020516276 A5 JP 2020516276A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- seq
- cell according
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014208A JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485670P | 2017-04-14 | 2017-04-14 | |
| US62/485,670 | 2017-04-14 | ||
| US201862629593P | 2018-02-12 | 2018-02-12 | |
| US62/629,593 | 2018-02-12 | ||
| PCT/US2018/027783 WO2018191748A1 (en) | 2017-04-14 | 2018-04-16 | Chimeric antigen receptor t cells targeting the tumor microenvironment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014208A Division JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516276A JP2020516276A (ja) | 2020-06-11 |
| JP2020516276A5 true JP2020516276A5 (enExample) | 2023-10-26 |
| JP7505885B2 JP7505885B2 (ja) | 2024-06-25 |
Family
ID=63793633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555484A Active JP7505885B2 (ja) | 2017-04-14 | 2018-04-16 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| JP2024014208A Pending JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014208A Pending JP2024062986A (ja) | 2017-04-14 | 2024-02-01 | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12378297B2 (enExample) |
| EP (2) | EP4759318A2 (enExample) |
| JP (2) | JP7505885B2 (enExample) |
| CN (1) | CN110520524A (enExample) |
| AU (3) | AU2018251206A1 (enExample) |
| CA (1) | CA3059444A1 (enExample) |
| WO (1) | WO2018191748A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| EP4759318A2 (en) | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| ES3068176T3 (en) * | 2018-02-12 | 2026-05-28 | Massachusetts Gen Hospital | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| TW202020146A (zh) * | 2018-07-26 | 2020-06-01 | 大陸商南京傳奇生物科技有限公司 | 含nef之t細胞及其產生方法 |
| WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| EP3947689A4 (en) * | 2019-03-27 | 2023-03-29 | National Research Council of Canada | ANTIGEN BINDING AGENTS SPECIFIC TO BINDING THE RECEPTOR VARIANT III OF THE EPIDERMAL GROWTH FACTOR |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| EP4010377A4 (en) * | 2019-08-09 | 2023-09-06 | A2 Biotherapeutics, Inc. | CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| CN113677704B (zh) * | 2019-11-22 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | Psma抗体及其应用 |
| WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| CN111235113A (zh) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | 包含嵌合抗原受体的免疫细胞及其用途 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP4097486A4 (en) | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| US11433100B2 (en) | 2020-08-20 | 2022-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| JP2023550148A (ja) * | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN115491358B (zh) * | 2021-06-17 | 2024-09-06 | 复星凯特生物科技有限公司 | 一种靶向b7-h3和folr1双打靶点car t的制备及应用 |
| WO2023274386A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向egfr的通用型car-t细胞及其制备方法 |
| TWI823402B (zh) * | 2021-07-21 | 2023-11-21 | 長聖國際生技股份有限公司 | 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物 |
| WO2023077068A1 (en) * | 2021-10-28 | 2023-05-04 | Skunkworx Bio, Inc. | Novel binding agents related to glycoprotein-a |
| CN116535518A (zh) * | 2022-08-03 | 2023-08-04 | 深圳市先康达生命科学有限公司 | 一种IL-15与DnTRII结合的融合蛋白及其应用 |
| WO2024192289A2 (en) * | 2023-03-14 | 2024-09-19 | The Wistar Institute Of Anatomy And Biology | Tri-specific t-cell engagers and methods of use in cancer therapeutics |
| WO2024196794A2 (en) * | 2023-03-17 | 2024-09-26 | The Children's Hospital Of Philadelphia | Compositions and methods for interneuron mediated delivery of cytotoxic agents to the brain |
| CN119708251A (zh) * | 2023-09-27 | 2025-03-28 | 北京大学 | 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法 |
| CN122295360A (zh) * | 2023-10-04 | 2026-06-26 | 俄亥俄州创新基金会 | 经由用嵌合抗原受体(car) t细胞疗法靶向调节性t细胞(treg)来调节肿瘤免疫微环境 |
| WO2025092689A1 (zh) * | 2023-10-30 | 2025-05-08 | 苏州沙砾生物科技有限公司 | 一种表达多特异性抗原结合蛋白的细胞及其应用 |
| WO2025140683A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京鼎成肽源生物技术有限公司 | 表达趋化因子10和白介素15的工程化免疫细胞 |
| WO2026020041A1 (en) * | 2024-07-17 | 2026-01-22 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2026022768A1 (ko) * | 2024-07-24 | 2026-01-29 | (주)티카로스 | 안전하며 효과적인 유전자세포치료 시스템 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9349368B1 (en) * | 2010-08-05 | 2016-05-24 | Google Inc. | Generating an audio notification based on detection of a triggering event |
| EP3459560B1 (en) * | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| US20160015749A1 (en) * | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Engager cells for immunotherapy |
| US20160017058A1 (en) | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| AU2014298373B2 (en) | 2013-08-01 | 2019-12-05 | Ludwig Institute For Cancer Research Ltd | Anti-GARP protein and uses thereof |
| JP6665102B2 (ja) | 2014-02-21 | 2020-03-13 | セレクティスＣｅｌｌｅｃｔｉｓ | 制御性ｔ細胞をインサイチューで阻害するための方法 |
| RU2017102769A (ru) * | 2014-07-29 | 2018-08-28 | Пфайзер Инк. | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| PL3212225T3 (pl) * | 2014-10-31 | 2026-03-30 | The Trustees Of The University Of Pennsylvania | Sposoby i kompozycje zmodyfikowanych limfocytów t |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| US10647778B2 (en) | 2015-02-09 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | Bi-specific chimeric antigen receptor and uses thereof |
| EP3297672B1 (en) * | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CA2999070A1 (en) * | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| CN105796597A (zh) | 2016-03-11 | 2016-07-27 | 江苏三特生物科技有限公司 | 携带pd-l1和ctla-4抗体基因的car-t细胞在肿瘤免疫上的应用 |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017173091A1 (en) | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| AU2017347686A1 (en) | 2016-10-19 | 2019-05-02 | Cellectis | Cell death inducing chimeric antigen receptors |
| US20200095301A1 (en) | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CN110520523A (zh) * | 2017-03-29 | 2019-11-29 | 台北医学大学 | 具抗原专一性的t细胞及其用途 |
| EP4759318A2 (en) | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| CN107326014B (zh) | 2017-07-31 | 2019-09-24 | 时力生物科技（北京）有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
| WO2019079034A1 (en) | 2017-10-17 | 2019-04-25 | The General Hospital Corporation | METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES |
| ES3068176T3 (en) | 2018-02-12 | 2026-05-28 | Massachusetts Gen Hospital | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| WO2022046935A2 (en) | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| EP4426723A4 (en) | 2021-11-04 | 2025-12-17 | Massachusetts Gen Hospital | ANTI-MESOTHELIN CAR T-CELL SECRETING TEAMS AND METHODS FOR THEM USE |
| CN119365202A (zh) | 2022-04-15 | 2025-01-24 | 总医院有限公司 | 包含结合cd33的t细胞接合抗体分子的结合cd70的car-t细胞 |
-
2018
- 2018-04-16 EP EP26158717.4A patent/EP4759318A2/en active Pending
- 2018-04-16 CN CN201880025361.8A patent/CN110520524A/zh active Pending
- 2018-04-16 EP EP18784599.5A patent/EP3609914B1/en active Active
- 2018-04-16 WO PCT/US2018/027783 patent/WO2018191748A1/en not_active Ceased
- 2018-04-16 US US16/603,675 patent/US12378297B2/en active Active
- 2018-04-16 JP JP2019555484A patent/JP7505885B2/ja active Active
- 2018-04-16 AU AU2018251206A patent/AU2018251206A1/en not_active Abandoned
- 2018-04-16 CA CA3059444A patent/CA3059444A1/en active Pending
-
2023
- 2023-09-28 US US18/477,532 patent/US20240075070A1/en active Pending
- 2023-12-07 AU AU2023278069A patent/AU2023278069B2/en active Active
-
2024
- 2024-02-01 JP JP2024014208A patent/JP2024062986A/ja active Pending
-
2025
- 2025-07-08 AU AU2025205213A patent/AU2025205213A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7341185B2 (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| US11136392B2 (en) | PD-1 immune modulating agents | |
| JP2021512635A5 (enExample) | ||
| JP2024062986A (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| CN111499753B (zh) | 双功能抗体及其用途 | |
| TW201825511A (zh) | 表現免疫檢查點調節子的溶瘤病毒 | |
| CN110035768A (zh) | 嵌合抗原受体 | |
| JP2015513394A (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| US20230348556A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| CN115403671A (zh) | 靶向Claudin18.2的纳米抗体及其用途 | |
| US20250051444A1 (en) | Multi-specific t cell engagers comprising lrrc15 antigen-binding domain | |
| JP2025540340A (ja) | キメラ抗原受容体 | |
| JP2024012258A (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| US20250302877A1 (en) | Anti-activated trop-2 chimeric antigen receptor constructs for use in cancer therapy | |
| EP4294830A2 (en) | Antibody-derived t cell activating technologies | |
| JP2024532486A5 (enExample) | ||
| EP4613779A1 (en) | Cd24 binding protein and use thereof | |
| CN115785269B (zh) | 抗pd-l1的抗体及其应用 | |
| US20260060935A1 (en) | Therapeutic effect enhancer for enhancing effect of car-t therapy | |
| US20260077046A1 (en) | Targeting the pvr axis using car t cell therapy and combinations | |
| US20240018236A1 (en) | Cd19-targeting humanized antibody and use thereof | |
| JP2023527462A (ja) | Ｃｄ２２に特異的な抗体およびその使用 | |
| HK40074322A (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same |